350 related articles for article (PubMed ID: 37052811)
1. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
2. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
3. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
6. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
9. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Madanat YF; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
Bewersdorf JP; Carraway H; Prebet T
Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
[TBL] [Abstract][Full Text] [Related]
11. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
[TBL] [Abstract][Full Text] [Related]
12. [Treating high-risk myelodysplastic syndromes].
Adès L
Bull Cancer; 2023 Nov; 110(11):1162-1167. PubMed ID: 37407322
[TBL] [Abstract][Full Text] [Related]
13. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
14. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS.
Aguirre LE; Komrokji R; Padron E
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101325. PubMed ID: 34865697
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
17. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
18. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
20. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]